Acquirer | Target | Price |
---|---|---|
EQT Partners | Press Ganey | $2.35 billion |
Carter Validus Mission Critical REIT II | HPI portfolio | $116.5 million |
Allergan plc | ForSight VISIONS | $95 million |
Scintilla Pharmaceuticals | SCILEX Pharmaceuticals | $70 million |
ZymeWorks Inc. | License to HuTARG platform | $65 million |